Metraipolis › archive › dc_d2bbe8859685

Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives — Europe PMC PMID:42645370

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42645370
DOI
10.3390/curroncol33080465
License (as archived)
solo-consultazione
Archived
2026-10-17T03:08:45.938Z
SHA-256 of the archived text
4472ec5d31a4801db8a2d6758ac5db80afa42442171537ba1c0f416dd4de4720
Stable URL of this page
https://metraipolis.com/documento/dc_d2bbe8859685

How to cite

Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives — Europe PMC PMID:42645370 — Europe PMC (en), https://europepmc.org/article/MED/42645370 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d2bbe8859685 (Metraipolis archive dc_d2bbe8859685, sha256 4472ec5d31a4801db8a2d6758ac5db80afa42442171537ba1c0f416dd4de4720)
BibTeX
@misc{dcd2bbe8859685,
  title = {Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives — Europe PMC PMID:42645370},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42645370},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d2bbe8859685; sha256 4472ec5d31a4801db8a2d6758ac5db80afa42442171537ba1c0f416dd4de4720},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42645370. Agents can read the archived copy with the MCP tool read_document.